{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T17:25:54Z","timestamp":1786296354145,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yakult BioScience Foundation"},{"name":"Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science","award":["KAKENHI: 18H03554, N. Nishida, and 18K07922, M Kudo"],"award-info":[{"award-number":["KAKENHI: 18H03554, N. Nishida, and 18K07922, M Kudo"]}]},{"DOI":"10.13039\/501100004330","name":"Smoking Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) are widely used to treat advanced metastatic cancers. Neutralisation of PD-1 or CTLA-4 by ICIs results in immune-related adverse events (irAEs). The clinicopathological features of twelve patients with hepatic irAEs were evaluated and compared to those of ten patients with autoimmune hepatitis (AIH) or graft-versus-host disease (GVHD). No significant difference was seen in serum levels of transaminases, whereas serum levels of IgG and anti-nuclear antibody were higher in patients with AIH than in those with GVHD or hepatic irAEs. Inflammation was limited to the liver lobes in patients with GVHD or hepatic irAEs, whereas patients with AIH exhibited both portal and lobular inflammation. Immunohistochemical analyses revealed a predominant infiltration of CD8<jats:sup>+<\/jats:sup> T cells and defective accumulation of regulatory T cells (Tregs) expressing forkhead box p3 (FOXP3) in the lobular areas of patients with hepatic irAEs and GVHD. In contrast, periportal lesions of patients with AIH were characterised by an infiltration of CD4<jats:sup>+<\/jats:sup> T cells, CD8<jats:sup>+<\/jats:sup> T cells, CD20<jats:sup>+<\/jats:sup> B cells, and FOXP3<jats:sup>+<\/jats:sup> Tregs. Overall, the activation of CD8<jats:sup>+<\/jats:sup> T cells in the absence of activation of Tregs potentially underlies the immunopathogenesis of hepatic irAEs.<\/jats:p>","DOI":"10.1038\/s41598-021-88824-1","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T10:05:37Z","timestamp":1619690737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Satoru","family":"Hagiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Minaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoriaki","family":"Komeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Cishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah-Mee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"88824_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25\u201339. https:\/\/doi.org\/10.1038\/s41577-019-0218-4 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"88824_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"88824_CR3","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974\u20131982. https:\/\/doi.org\/10.1200\/JCO.2014.59.4358 (2015).","journal-title":"J. Clin. Oncol."},{"key":"88824_CR4","doi-asserted-by":"publisher","first-page":"e11936","DOI":"10.1097\/MD.0000000000011936","volume":"97","author":"M Khan","year":"2018","unstructured":"Khan, M. et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 97, e11936. https:\/\/doi.org\/10.1097\/MD.0000000000011936 (2018).","journal-title":"Medicine (Baltimore)"},{"key":"88824_CR5","doi-asserted-by":"publisher","first-page":"FSO341","DOI":"10.4155\/fsoa-2018-0033","volume":"4","author":"E Seront","year":"2018","unstructured":"Seront, E., Catala, G., Dermine, A., Lejeune, S. & Rysselinck, S. Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma. Future Sci. OA 4, FSO341. https:\/\/doi.org\/10.4155\/fsoa-2018-0033 (2018).","journal-title":"Future Sci. OA"},{"key":"88824_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000489099","volume":"41","author":"E Smyth","year":"2018","unstructured":"Smyth, E. & Thuss-Patience, P. C. Immune checkpoint inhibition in gastro-oesophageal cancer. Oncol. Res. Treat. 41, 272\u2013280. https:\/\/doi.org\/10.1159\/000489099 (2018).","journal-title":"Oncol. Res. Treat."},{"key":"88824_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1055\/s-0038-1667358","volume":"38","author":"BA Nadeau","year":"2018","unstructured":"Nadeau, B. A., Fecher, L. A., Owens, S. R. & Razumilava, N. Liver toxicity with cancer checkpoint inhibitor therapy. Semin. Liver Dis. 38, 366\u2013378. https:\/\/doi.org\/10.1055\/s-0038-1667358 (2018).","journal-title":"Semin. Liver Dis."},{"key":"88824_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"88824_CR9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman, C. F., Proverbs-Singh, T. A. & Postow, M. A. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2, 1346\u20131353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051 (2016).","journal-title":"JAMA Oncol."},{"key":"88824_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi, S. et al. Regulatory T cells and human disease. Annu. Rev. Immunol. 38, 541\u2013566. https:\/\/doi.org\/10.1146\/annurev-immunol-042718-041717 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"88824_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356\u2013371. https:\/\/doi.org\/10.1038\/s41571-019-0175-7 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"88824_CR12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1172\/JCI25112","volume":"116","author":"R Bacchetta","year":"2006","unstructured":"Bacchetta, R. et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J. Clin. Invest. 116, 1713\u20131722. https:\/\/doi.org\/10.1172\/JCI25112 (2006).","journal-title":"J. Clin. Invest."},{"key":"88824_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/MOP.0000000000000029","volume":"25","author":"JW Verbsky","year":"2013","unstructured":"Verbsky, J. W. & Chatila, T. A. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr. Opin. Pediatr. 25, 708\u2013714. https:\/\/doi.org\/10.1097\/MOP.0000000000000029 (2013).","journal-title":"Curr. Opin. Pediatr."},{"key":"88824_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/s0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez, F. et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31, 929\u2013938. https:\/\/doi.org\/10.1016\/s0168-8278(99)80297-9 (1999).","journal-title":"J. Hepatol."},{"key":"88824_CR15","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans, H. M. et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 53, 1401\u20131415. https:\/\/doi.org\/10.1038\/s41409-018-0204-7 (2018).","journal-title":"Bone Marrow Transplant."},{"key":"88824_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin, E. et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J. Hepatol. 68, 1181\u20131190. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.033 (2018).","journal-title":"J. Hepatol."},{"key":"88824_CR17","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/mi.2015.144","volume":"9","author":"T Watanabe","year":"2016","unstructured":"Watanabe, T. et al. Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis. Mucosal Immunol. 9, 1234\u20131249. https:\/\/doi.org\/10.1038\/mi.2015.144 (2016).","journal-title":"Mucosal Immunol."},{"key":"88824_CR18","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.4049\/jimmunol.1700060","volume":"198","author":"T Watanabe","year":"2017","unstructured":"Watanabe, T. et al. Chronic fibro-inflammatory responses in autoimmune pancreatitis depend on IFN-alpha and IL-33 produced by plasmacytoid dendritic cells. J. Immunol. 198, 3886\u20133896. https:\/\/doi.org\/10.4049\/jimmunol.1700060 (2017).","journal-title":"J. Immunol."},{"key":"88824_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen, Y. & Yeh, M. M. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod. Pathol. 31, 965\u2013973. https:\/\/doi.org\/10.1038\/s41379-018-0013-y (2018).","journal-title":"Mod. Pathol."},{"key":"88824_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","volume":"34","author":"JV Cohen","year":"2021","unstructured":"Cohen, J. V. et al. Liver biopsy findings in patients on immune checkpoint inhibitors. Mod. Pathol. 34, 426\u2013437. https:\/\/doi.org\/10.1038\/s41379-020-00653-1 (2021).","journal-title":"Mod. Pathol."},{"key":"88824_CR21","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.it.2004.09.006","volume":"25","author":"K Klugewitz","year":"2004","unstructured":"Klugewitz, K., Adams, D. H., Emoto, M., Eulenburg, K. & Hamann, A. The composition of intrahepatic lymphocytes: shaped by selective recruitment?. Trends Immunol. 25, 590\u2013594. https:\/\/doi.org\/10.1016\/j.it.2004.09.006 (2004).","journal-title":"Trends Immunol."},{"key":"88824_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3389\/fimmu.2019.00946","volume":"10","author":"J Mikulak","year":"2019","unstructured":"Mikulak, J., Bruni, E., Oriolo, F., Di Vito, C. & Mavilio, D. Hepatic natural killer cells: organ-specific sentinels of liver immune homeostasis and physiopathology. Front. Immunol. 10, 946. https:\/\/doi.org\/10.3389\/fimmu.2019.00946 (2019).","journal-title":"Front. Immunol."},{"key":"88824_CR23","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.4049\/jimmunol.174.5.3051","volume":"174","author":"Y Zhang","year":"2005","unstructured":"Zhang, Y., Joe, G., Hexner, E., Zhu, J. & Emerson, S. G. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J. Immunol. 174, 3051\u20133058. https:\/\/doi.org\/10.4049\/jimmunol.174.5.3051 (2005).","journal-title":"J. Immunol."},{"key":"88824_CR24","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1326","volume":"11","author":"Y Zhang","year":"2005","unstructured":"Zhang, Y., Joe, G., Hexner, E., Zhu, J. & Emerson, S. G. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat. Med. 11, 1299\u20131305. https:\/\/doi.org\/10.1038\/nm1326 (2005).","journal-title":"Nat. Med."},{"key":"88824_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4049\/jimmunol.1102630","volume":"188","author":"X Li","year":"2012","unstructured":"Li, X. et al. Loss of B7\u2013H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease. J. Immunol. 188, 724\u2013734. https:\/\/doi.org\/10.4049\/jimmunol.1102630 (2012).","journal-title":"J. Immunol."},{"key":"88824_CR26","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.3389\/fimmu.2018.03061","volume":"9","author":"K Cassady","year":"2018","unstructured":"Cassady, K., Martin, P. J. & Zeng, D. Regulation of GVHD and GVL activity via PD-L1 interaction with PD-1 and CD80. Front. Immunol. 9, 3061. https:\/\/doi.org\/10.3389\/fimmu.2018.03061 (2018).","journal-title":"Front. Immunol."},{"key":"88824_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/ni1437","volume":"8","author":"LM Williams","year":"2007","unstructured":"Williams, L. M. & Rudensky, A. Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8, 277\u2013284. https:\/\/doi.org\/10.1038\/ni1437 (2007).","journal-title":"Nat. Immunol."},{"key":"88824_CR28","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2016-09-741629","volume":"129","author":"T Asano","year":"2017","unstructured":"Asano, T. et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood 129, 2186\u20132197. https:\/\/doi.org\/10.1182\/blood-2016-09-741629 (2017).","journal-title":"Blood"},{"key":"88824_CR29","doi-asserted-by":"publisher","first-page":"179ra143","DOI":"10.1126\/scitranslmed.3005265","volume":"5","author":"K Matsuoka","year":"2013","unstructured":"Matsuoka, K. et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci. Transl. Med. 5, 179ra143. https:\/\/doi.org\/10.1126\/scitranslmed.3005265 (2013).","journal-title":"Sci. Transl. Med."},{"key":"88824_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.it.2019.11.005","volume":"41","author":"KL Hippen","year":"2020","unstructured":"Hippen, K. L., Aguilar, E. G., Rhee, S. Y., Bolivar-Wagers, S. & Blazar, B. R. Distinct regulatory and effector T cell metabolic demands during graft-versus-host disease. Trends Immunol. 41, 77\u201391. https:\/\/doi.org\/10.1016\/j.it.2019.11.005 (2020).","journal-title":"Trends Immunol."},{"issue":"1322\u20131333","key":"88824_CR31","doi-asserted-by":"publisher","first-page":"e1321","DOI":"10.1053\/j.gastro.2011.01.002","volume":"140","author":"N Aoki","year":"2011","unstructured":"Aoki, N. et al. Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice. Gastroenterology 140(1322\u20131333), e1321-1325. https:\/\/doi.org\/10.1053\/j.gastro.2011.01.002 (2011).","journal-title":"Gastroenterology"},{"key":"88824_CR32","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-16-0194","volume":"76","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer. Cancer Res. 76, 5288\u20135301. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0194 (2016).","journal-title":"Cancer Res."},{"key":"88824_CR33","doi-asserted-by":"publisher","first-page":"9437043","DOI":"10.1155\/2019\/9437043","volume":"2019","author":"E Sucher","year":"2019","unstructured":"Sucher, E. et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J. Immunol. Res. 2019, 9437043. https:\/\/doi.org\/10.1155\/2019\/9437043 (2019).","journal-title":"J. Immunol. Res."},{"key":"88824_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jhep.2012.02.029","volume":"57","author":"M Peiseler","year":"2012","unstructured":"Peiseler, M. et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J. Hepatol. 57, 125\u2013132. https:\/\/doi.org\/10.1016\/j.jhep.2012.02.029 (2012).","journal-title":"J. Hepatol."},{"key":"88824_CR35","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","volume":"61","author":"R Taubert","year":"2014","unstructured":"Taubert, R. et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J. Hepatol. 61, 1106\u20131114. https:\/\/doi.org\/10.1016\/j.jhep.2014.05.034 (2014).","journal-title":"J. Hepatol."},{"key":"88824_CR36","doi-asserted-by":"publisher","first-page":"e0181107","DOI":"10.1371\/journal.pone.0181107","volume":"12","author":"J Diestelhorst","year":"2017","unstructured":"Diestelhorst, J. et al. Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy. PLoS ONE 12, e0181107. https:\/\/doi.org\/10.1371\/journal.pone.0181107 (2017).","journal-title":"PLoS ONE"},{"key":"88824_CR37","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/hep4.1202","volume":"2","author":"A Renand","year":"2018","unstructured":"Renand, A. et al. Immune alterations in patients with type 1 autoimmune hepatitis persist upon standard immunosuppressive treatment. Hepatol. Commun. 2, 968\u2013981. https:\/\/doi.org\/10.1002\/hep4.1202 (2018).","journal-title":"Hepatol. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88824-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88824-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88824-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:34:57Z","timestamp":1670052897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88824-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88824"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88824-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"25 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9242"}}